electroCore, Inc. (ECOR)

NASDAQ: ECOR · Real-Time Price · USD
7.25
+0.09 (1.26%)
Oct 2, 2024, 4:00 PM EDT - Market closed
1.26%
Market Cap 46.74M
Revenue (ttm) 21.28M
Net Income (ttm) -14.23M
Shares Out 6.45M
EPS (ttm) -2.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 26,842
Open 7.02
Previous Close 7.16
Day's Range 7.02 - 7.32
52-Week Range 4.90 - 8.08
Beta 0.63
Analysts Strong Buy
Price Target 15.00 (+106.9%)
Earnings Date Nov 6, 2024

About ECOR

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general healt... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jun 22, 2018
Employees 68
Stock Exchange NASDAQ
Ticker Symbol ECOR
Full Company Profile

Financial Performance

In 2023, electroCore's revenue was $16.03 million, an increase of 86.57% compared to the previous year's $8.59 million. Losses were -$18.83 million, -15.02% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for ECOR stock is "Strong Buy" and the 12-month stock price forecast is $15.0.

Price Target
$15.0
(106.90% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Study Suggests Non-invasive Vagus Nerve Stimulation (nVNS) is effective in accelerating United States Air Force Pilot Training

Clinical trial demonstrates the ability of nVNS to accelerate sensorimotor learning in USAF Simulator Based Pilot Training Clinical trial demonstrates the ability of nVNS to accelerate sensorimotor le...

22 days ago - GlobeNewsWire

electroCore to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

ROCKAWAY, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in th...

4 weeks ago - GlobeNewsWire

electroCore, Inc. (ECOR) Q2 2024 Earnings Call Transcript

electroCore, Inc. (NASDAQ:ECOR) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO Brian Posner - CFO Conference Call Participants Jeffrey Cohen - La...

7 weeks ago - Seeking Alpha

electroCore to Participate in Upcoming Investor Conferences

ROCKAWAY, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company's CEO, Dan Goldberg...

7 weeks ago - GlobeNewsWire

electroCore Announces Second Quarter 2024 Financial Results

Seventh consecutive record quarterly net sales of $6.1 million, an increase of 73% over second quarter 2023  Company to host a conference call and webcast today, August 7, 2024 at 4:30 PM EST ROCKAWAY...

2 months ago - GlobeNewsWire

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

ROCKAWAY, N.J., Aug. 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that on August 1, 2...

2 months ago - GlobeNewsWire

electroCore Announces the Commercial Launch of TAC-STIM™

ROCKAWAY, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is thrilled to announce the Commercial Off the Shelf...

3 months ago - GlobeNewsWire

electroCore, Inc. Announces $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules

ROCKAWAY, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced tha...

4 months ago - GlobeNewsWire

electroCore, Inc. (ECOR) Q1 2024 Earnings Call Transcript

electroCore, Inc. (NASDAQ:ECOR) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO Brian Posner - CFO Conference Call Participants Jeffrey Cohen - Laden...

5 months ago - Seeking Alpha

electroCore Announces First Quarter 2024 Financial Results

Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023 Company to host a conference call and webcast today, May 8, 2024 at 4:30 PM EST

5 months ago - GlobeNewsWire

electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024

ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results...

5 months ago - GlobeNewsWire

Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion

ROCKAWAY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of its...

5 months ago - GlobeNewsWire

electroCore Announces the Launch of Truvaga Plus® for General Wellness

ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consume...

6 months ago - GlobeNewsWire

electroCore Expands Intellectual Property Portfolio

ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue n...

6 months ago - GlobeNewsWire

electroCore, Inc. (ECOR) Q4 2023 Earnings Call Transcript

electroCore, Inc. (ECOR) Q4 2023 Earnings Call Transcript

7 months ago - Seeking Alpha

electroCore Announces Fourth Quarter and Full Year 2023 Financial Results

Record full year 2023  net sales of $ 16.0 million increased 87%  over $8.6  million for the full year 2022

7 months ago - GlobeNewsWire

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024

ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial resul...

7 months ago - GlobeNewsWire

electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Tradema...

10 months ago - GlobeNewsWire

Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023

ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company's Chief Medical Off...

11 months ago - GlobeNewsWire

electroCore, Inc. (ECOR) Q3 2023 Earnings Call Transcript

electroCore, Inc. (NASDAQ:ECOR) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Dan Goldberger – Chief Executive Officer Brian Posner – Chief Financial Officer Confe...

11 months ago - Seeking Alpha

electroCore Announces Third Quarter 2023 Financial Results

Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5 million  C...

11 months ago - GlobeNewsWire

electroCore to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is...

11 months ago - GlobeNewsWire

Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting

Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia Clinical Trial suggests nVNS can reduce the use of rescue...

1 year ago - GlobeNewsWire

electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue

ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue...

1 year ago - GlobeNewsWire

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Tradema...

1 year ago - GlobeNewsWire